Panacea Biotec

how big is Panacea Biotec?

As of Jun 06, Panacea Biotec Ltd has a market capitalization of 2,740.36 Cr, classifying it as a Small Cap company, with net sales of 559.09 Cr and a net profit of -8.54 Cr for the latest four quarters. The company has shareholder's funds of 842.05 Cr and total assets of 1,240.67 Cr as of the latest annual period ending in Mar 24.

Market Cap: As of Jun 06, Panacea Biotec Ltd has a market capitalization of 2,740.36 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Panacea Biotec reported net sales of 559.09 Cr and a net profit of -8.54 Cr. This data is on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the latest annual period ending in Mar 24. The company has shareholder's funds amounting to 842.05 Cr and total assets of 1,240.67 Cr.

What does Panacea Biotec do?

Panacea Biotec Ltd is a leading Indian research-based health management company in the Pharmaceuticals & Biotechnology sector, with a market cap of Rs 2,750 Cr. As of March 2025, it reported net sales of 133 Cr and a net loss of 2 Cr.

Overview:<BR>Panacea Biotec Ltd is India's leading research-based health management company operating in the Pharmaceuticals & Biotechnology industry within the small-cap market segment.<BR><BR>History:<BR>The company was incorporated on February 2, 1984, originally under the name Panacea Drug (P) Ltd. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 133 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -2 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 2,750 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.11 <BR>Return on Equity: -5.33% <BR>Price to Book: 3.46<BR><BR>Contact Details:<BR>Address: Ambala-Chandigarh Highway, Lalru Punjab: 140501 <BR>Phone: 91-1762-505900 <BR>Email: companysec@panaceabiotec.com <BR>Website: http://www.panaceabiotec.com

Who are in the management team of Panacea Biotec?

As of March 2022, the management team of Panacea Biotec includes Chairman Rajesh Jain, Joint Managing Director Sandeep Jain, Group CFO Vinod Goel, and several independent directors, totaling a mix of executive and non-executive members.

As of March 2022, the management team of Panacea Biotec includes the following individuals:<BR><BR>1. Soshil Kumar Jain - Chairman & Executive Director<BR>2. Rajesh Jain - Chairman & Managing Director<BR>3. Sandeep Jain - Joint Managing Director<BR>4. R L Narasimhan - Non-Executive & Independent Director<BR>5. N N Khamitkar - Non-Executive & Independent Director<BR>6. K M Lal - Non-Executive & Independent Director<BR>7. Vinod Goel - Group CFO & Company Secretary<BR>8. Manjula Upadhyay - Non-Executive & Independent Director<BR>9. Mukul Gupta - Non-Executive & Independent Director<BR>10. Ankesh Jain - Whole-time Director<BR>11. Bhupinder Singh - Non-Executive & Independent Director<BR>12. Narotam Kumar Juneja - Director<BR><BR>This team comprises a mix of executive and non-executive members, with various roles contributing to the company's governance and management.

Has Panacea Biotec declared dividend?

Yes, Panacea Biotec Ltd has declared a 75% dividend, amounting to ₹0.75 per share, with an ex-date of September 19, 2011. However, the dividend yield is 0%, as it has not contributed to returns in recent periods, despite significant price returns.

Panacea Biotec Ltd has declared a 75% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 75%<BR>- Amount per share: 0.75<BR>- Ex-date: 19 Sep 11<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was 2.49%, the dividend return was 0%, resulting in a total return of 2.49%.<BR><BR>For the 1-year period, the price return was 253.27%, the dividend return was 0%, leading to a total return of 253.27%.<BR><BR>Over the 2-year period, the price return was 272.84%, with a dividend return of 0%, culminating in a total return of 272.84%.<BR><BR>In the 3-year period, the price return was 203.06%, the dividend return was 0%, resulting in a total return of 203.06%.<BR><BR>For the 4-year period, the price return was 15.05%, with a dividend return of 0%, leading to a total return of 15.05%.<BR><BR>In the 5-year period, the price return was 177.17%, the dividend return was 0%, culminating in a total return of 177.17%.<BR><BR>Overall, while Panacea Biotec has declared a dividend, the dividend yield is 0%, indicating that the dividend has not contributed to returns in recent periods. The company has experienced significant price returns over various periods, suggesting strong performance in its stock value.

Who are the peers of the Panacea Biotec?

Panacea Biotec's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Orchid Pharma, IOL Chemicals, Novartis India, and Senores Pharma. Panacea Biotec has the highest 1-year return at 269.46%, while Orchid Pharma has the lowest at -31.48%.

Peers: The peers of Panacea Biotec are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Orchid Pharma, IOL Chemicals, Novartis India, and Senores Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at IOL Chemicals and Novartis India. Below Average management risk is noted for Orchid Pharma, Panacea Biotec, and Senores Pharma. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen in Divi's Lab., Torrent Pharma, Orchid Pharma, Panacea Biotec, and Zota Health Care. Average growth is noted for IOL Chemicals and Novartis India, with Excellent growth at Senores Pharma. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, and IOL Chemicals, while Good capital structure is found at Torrent Pharma and Senores Pharma. Below Average capital structure is observed at Orchid Pharma, Panacea Biotec, and Zota Health Care.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Panacea Biotec at 269.46%, while the lowest is Orchid Pharma at -31.48%. Panacea Biotec's 1-year return significantly exceeds all its peers. Additionally, Orchid Pharma and Zota Health Care have negative six-month returns.

Is Panacea Biotec overvalued or undervalued?

As of November 13, 2020, Panacea Biotec is considered risky and overvalued with a negative PE ratio of -61.96 and an EV to EBITDA of -103.02, significantly worse than its peers, despite a 252.56% return over the past year.

As of 13 November 2020, the valuation grade for Panacea Biotec has moved from very expensive to risky, indicating a significant shift in its perceived value. The company is currently assessed as overvalued, given its negative PE ratio of -61.96 and EV to EBITDA ratio of -103.02, which are starkly contrasting with its peers. The Price to Book Value stands at 3.30, suggesting that the market is pricing the company at a premium despite its financial struggles.<BR><BR>In comparison to its peers, Panacea Biotec's ratios are considerably worse; for instance, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla shows a PE of 22.99 and an EV to EBITDA of 15.93. These comparisons highlight the challenges Panacea Biotec faces in the market. Additionally, while the company has shown impressive returns over the past year at 252.56%, this performance is not enough to justify its current valuation in light of its financial metrics.

Who are the top shareholders of the Panacea Biotec?

The top shareholder of Panacea Biotec is Dr. Rajesh Jain, who holds 49.33% of the shares. Individual investors own 18.45%, while 14 foreign institutional investors hold a combined 1.16%, with no mutual funds currently invested.

The top shareholders of Panacea Biotec include the promoters, with Dr. Rajesh Jain holding the highest stake at 49.33%. There are no pledged promoter holdings, and individual investors collectively hold 18.45% of the shares. Additionally, 14 foreign institutional investors (FIIs) hold a combined 1.16% of the company. There are no mutual funds currently holding shares in Panacea Biotec.

When is the next results date for Panacea Biotec?

The next results date for Panacea Biotec is 14 August 2025.

The next results date for Panacea Biotec is scheduled for 14 August 2025.

Are Panacea Biotec latest results good or bad?

Panacea Biotec's latest results show strong year-on-year sales growth of 44.05% and a 125.63% increase in net profit, but concerns about declining liquidity and a flat overall performance warrant caution. The stock has received a 'Strong Sell' rating from MarketsMOJO.

Panacea Biotec's latest results present a mixed picture. On the positive side, the company reported a significant year-on-year growth in net sales of 44.05%, reaching Rs 166.70 crore, which is the highest quarterly sales in the last five quarters. Additionally, the consolidated net profit saw a remarkable increase of 125.63%, indicating improved profitability compared to the previous year.<BR><BR>However, there are notable challenges as well. The company's cash and cash equivalents have dropped to Rs 106.97 crore, raising concerns about its short-term liquidity. This deterioration could impact operational flexibility in the future. Furthermore, despite the positive sales growth, the overall financial performance for the quarter has been described as flat, and the stock has received a 'Strong Sell' rating from MarketsMOJO.<BR><BR>In summary, while Panacea Biotec shows strong sales and profit growth, liquidity issues and a flat overall performance suggest caution moving forward.

How has been the historical performance of Panacea Biotec?

Panacea Biotec's historical performance shows fluctuating financial metrics, with stable net sales but increasing operating losses, resulting in a decline in profit before and after tax. Despite a slight increase in total assets and improved cash flow from investing activities, the company faces challenges in profitability.

Answer:<BR>The historical performance of Panacea Biotec shows a fluctuating trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Panacea Biotec's net sales have remained relatively stable, with a slight decrease from 559.17 crore in March 2024 to 559.09 crore in March 2025, following a notable drop from 661.23 crore in March 2022. The total operating income mirrored this trend, peaking at 661.23 crore in March 2022 before declining to 559.09 crore in March 2025. The company's total expenditure, excluding depreciation, increased from 579.23 crore in March 2024 to 585.00 crore in March 2025, contributing to an operating loss of 25.91 crore in March 2025, compared to a loss of 20.06 crore in March 2024. Profit before tax also saw a decline, moving from a profit of 1.48 crore in March 2024 to a loss of 7.95 crore in March 2025. Consequently, the profit after tax worsened from a loss of 1.50 crore in March 2024 to a loss of 8.72 crore in March 2025. The company's total assets increased slightly from 1,240.82 crore in March 2024 to 1,289.75 crore in March 2025, while total liabilities also rose from 1,240.82 crore to 1,289.75 crore during the same period. Cash flow from operating activities remained negative at -27.00 crore in March 2025, although cash flow from investing activities improved significantly to 64.00 crore. Overall, the financial performance of Panacea Biotec reflects challenges in profitability despite stable revenue figures.

Should I buy, sell or hold Panacea Biotec?

Is Panacea Biotec technically bullish or bearish?

As of December 1, 2025, Panacea Biotec's technical trend is bearish, supported by bearish signals from the weekly MACD and KST, daily moving averages, and a lack of strong indicators from the RSI and Dow Theory, despite mildly bullish monthly Bollinger Bands.

As of 1 December 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Panacea Biotec is bearish, with a moderate strength indicated by the weekly MACD and KST both showing bearish signals. The daily moving averages also confirm a bearish outlook. Although the monthly Bollinger Bands are mildly bullish, they do not outweigh the bearish indicators present in the weekly timeframe. Overall, the lack of significant signals from the RSI and Dow Theory further supports a bearish sentiment.

Which are the latest news on Panacea Biotec?

Why is Panacea Biotec Ltd falling/rising?

As of 03-Feb, Panacea Biotec Ltd's stock price is rising to Rs 371.00, reflecting a short-term increase despite significant long-term challenges, including weak fundamentals and declining investor confidence. The stock has outperformed the Sensex recently, but underlying issues such as operating losses and poor debt servicing raise concerns about its financial health.

As of 03-Feb, Panacea Biotec Ltd's stock price is rising, currently at Rs 371.00, reflecting an increase of Rs 4.75 or 1.3%. This rise follows a trend reversal after two consecutive days of decline. The stock has shown a weekly gain of 6.93%, outperforming the Sensex, which has only increased by 2.30% over the same period. Additionally, the stock reached an intraday high of Rs 381.35, indicating positive momentum during the trading day.<BR><BR>However, despite this short-term rise, there are significant underlying challenges for the company. The stock has underperformed its sector by 1.49% today, and there is a notable decline in investor participation, with delivery volume dropping by 53.09% compared to the five-day average. Furthermore, the company's long-term fundamentals are weak, characterized by operating losses and a negative EBITDA, which raises concerns about its financial health. The company's net sales have decreased at an annual rate of -0.13%, and its ability to service debt is poor, as indicated by a negative EBIT to Interest ratio.<BR><BR>In summary, while the stock is experiencing a temporary rise due to short-term trading dynamics and sector performance, the long-term outlook remains precarious due to fundamental weaknesses and declining investor confidence.